Global Blood Therapeutics will be acquired by Pfizer for $5.4 billion to enhance its presence in rare hematology

Today, Pfizer Inc. and Global Blood Therapeutics, Inc. announced that the companies had entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company that provides hope to underserved patient communities, beginning with sickle cell disease (SCD), by discovering, developing, and delivering life-changing treatments.

It strengthens Pfizer’s commitment to SCD by bringing expertise and a leading pipeline that will address the full spectrum of critical needs in this underserved community. The acquisition complements and enhances Pfizer’s more than 30-year heritage in rare hematology. As part of its commitment to and engagement with the SCD community, Pfizer intends to continue to build on its existing engagement and commitment to the community.

Follow us:

Share this article: